Real-world Data for High-risk Stage II Colorectal Cancer - The Role of Tumor Side in the Adjuvant Setting
Carregando...
Citações na Scopus
1
Tipo de produção
article
Data de publicação
2021
Título da Revista
ISSN da Revista
Título do Volume
Editora
CIG MEDIA GROUP, LP
Citação
CLINICAL COLORECTAL CANCER, v.20, n.2, p.E100-E108, 2021
Resumo
The impact of sidedness in the high-risk stage II colorectal cancer setting is uncertain. Although controversial, data suggest a modest benefit of adjuvant chemotherapy in this scenario. This study analyzes the overall survival and recurrence-free survival according to the tumor side and considers adjuvant chemotherapy exposure and clinical and molecular features. In this retrospective cohort, the tumor side did not influence overall survival. Background: The impact of sidedness in the high-risk stage II colorectal cancer (CRC) setting is uncertain. Although controversial, available data suggest a possible modest benefit of adjuvant chemotherapy (CT) in the adjuvant scenario. The aim of this study is to analyze the overall survival (OS) and recurrence-free survival (RFS) according to the tumor side. Patients and Methods: In this single-center retrospective cohort, we analyzed patients treated between January 2011 and December 2018. We evaluated OS and RFS of high-risk patients according to the tumor side and considering adjuvant CT exposure and clinical and molecular features. Results: A total of 1047 patients with stage II CRC were evaluated. Of these, 540 had high-risk criteria and microsatellite stability (MSS) or unknown status. One hundred fifty-seven (29%) patients had right-sided tumors, and 352 (65.2%) had left-sided tumors. Most patients received adjuvant CT, and the majority of them had T3 stage tumors, >= 12 lymph node resection, left tumor, MSS, and moderate differentiation. OS did not differ according to tumor side (5-year OS rates: 81.9% for right-sided tumors vs. 83% for left-sided tumors; hazard ratio, 0.91; 95% confidence interval, 0.55-1.53; P = .744). Adjuvant CT was associated with a superior RFS and OS, with 5-year OS rates of 87.7% versus 76.1% in the no-adjuvant group (hazard ratio, 0.46; 95% CI, 0.28-0.73; P = .001). Conclusion: The tumor side did not influence the outcomes in this study. Adjuvant CT was associated with improved RFS and OS in patients with high-risk stage II CRC, with a total gain of 11.6% in 5-year OS.
Palavras-chave
Adjuvant therapy, Colorectal cancer, Early stage, Gastrointestinal cancer, Sidedness
Referências
- Andre T, 2004, NEW ENGL J MED, V350, P2343, DOI 10.1056/NEJMoa032709
- [Anonymous], 2019, ESTIMATE 2020 CANC I
- Ghidini M, 2018, CURR TREAT OPTION ON, V19, DOI 10.1007/s11864-018-0544-y
- Gray R, 2007, LANCET, V370, P2020, DOI 10.1016/s0140-6736(07)61866-2
- Guinney J, 2015, NAT MED, V21, P1350, DOI 10.1038/nm.3967
- Karim S, 2017, JAMA ONCOL, V3, P1386, DOI 10.1001/jamaoncol.2017.1016
- Kuebler JP, 2007, J CLIN ONCOL, V25, P2198, DOI 10.1200/JCO.2006.08.2974
- LABIANCA R, 1995, LANCET, V345, P939
- Lee MM, 2018, CLIN COLORECTAL CANC, V17, pE569, DOI 10.1016/j.clcc.2018.05.008
- Lee MS, 2017, J NATL COMPR CANC NE, V15, P411, DOI 10.6004/jnccn.2017.0038
- Meguid RA, 2008, ANN SURG ONCOL, V15, P2388, DOI 10.1245/s10434-008-0015-y
- MOERTEL CG, 1990, NEW ENGL J MED, V322, P352, DOI 10.1056/NEJM199002083220602
- Negri F, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-40096-6
- O'Connor ES, 2011, J CLIN ONCOL, V29, P3381, DOI 10.1200/JCO.2010.34.3426
- Petrelli F, 2017, JAMA ONCOL, V3, P211, DOI 10.1001/jamaoncol.2016.4227
- Ribic CM, 2003, NEW ENGL J MED, V349, P247, DOI 10.1056/NEJMoa022289
- Salem ME, 2017, ONCOTARGET, V8, P86356, DOI 10.18632/oncotarget.21169
- Sargent D, 2009, J CLIN ONCOL, V27, P872, DOI 10.1200/JCO.2008.19.5362
- Ulanja MB, 2019, J ONCOL, V2019, DOI 10.1155/2019/4315032
- Wang CY, 2017, JCO CLIN CANCER INFO, V1, DOI 10.1200/CCI.17.00099
- Weiss JM, 2011, J CLIN ONCOL, V29, P4401, DOI 10.1200/JCO.2011.36.4414